文档介绍：HMG CoA还原酶抑制剂对肾病综合征大鼠肝脏高密度脂蛋白受体表达的影响
【摘要】目的: 在大鼠肾病模型中观察使用3羟基3甲基戊二酰辅酶A(HMGCoA)还原酶抑制剂洛伐他汀治疗对肝脏高密度脂蛋白(HDL)受体表达的影响,探讨他汀类药治疗肾病综合征高脂血症的机制. 方法: 给予大鼠2次尾静脉注射阿霉素建立肾病综合征大鼠模型;采用灌胃法给予大鼠洛伐他汀治疗2 wk;采用Western Blot和RTPCR技术分别检测HDL受体蛋白和其mRNA在肝脏的表达,同时检测大鼠相关血生化指标. 结果: 给予肾病综合征大鼠洛伐他汀治疗2 wk后,血清总胆固醇、高密度脂蛋白胆固醇和三酰甘油以及尿蛋白均显著降低,血清白蛋白显著升高(P<);血肌酐与对照组比较差异无统计学意义(P>);肝脏HDL受体蛋白与肾病综合征组比较显著增加(±±, P<);肝脏HDL受体mRNA与肾病综合征组比较无统计学意义(±±,P>). 结论: 肾病综合征大鼠经洛伐他汀治疗后,肝脏HDL受体的缺乏得到明显改善,同时大鼠高胆固醇血症降低.
【关键词】肾病综合征; 大鼠; 洛伐他汀; 受体,HDL
【Abstract】AIM: To observe the effects of HMGCoA (3hydroxy3methylglutaryCoA) reductase inhibitor on hepatic expression of high density lipoprotein (HDL) receptor in nephrotic rats. METHODS: Adriamycin
induced nephrotic rat models were established by twice injection of adriamycin via the tail vein. Nephrotic rats were treated with either lovastatin(20 mg/kg·d) or placebo for 2 weeks. The expressions of hepatic HDL receptor gene and protein were detected with Western Blot and RTPCR, respectirely. Related serum biochemical parameters were examined. RESULTS: After 2 weeks of lovastatin administration, serum levels of total cholesterol, HDL cholesterol, triglyceride and urinary protein excretion were significantly decreased, serum albumin was significantly increased in study group(P<0.